Shanghai Zerun Biotechnology Co.,Ltd

ENGLISH  中文


Incorporated in 2003, Shanghai Zerun Biotechnology Co., Ltd. is located in Zhangjiang High-Tech Park in Pudong, Shanghai, China. The company is an innovation driven biotech with a complete set of platforms dedicated to novel human vaccine and biopharmaceutical research, development and commercialization. Zerun is a government designated “high-tech enterprise” that is carrying out multiple government funded “National Key New Drug Development Projects”. Zerun has a mission to become a leading biotech player at the forefront of key innovative medicine development in China. At the end of 2012, Zerun successfully merged with and became a subsidiary of Walvax Biotechnology Co., Ltd. Zerun will follow Walvax’s goal of becoming one of world's trustworthy biopharmaceutical enterprises, and  be in step with Walvax’s mission of "advance science and technology for the benefit of mankind".


Beside Zerun’s strength in R&D and technology, what makes the company stand out from the rest of the industry as following: (1) its core team is composed of a group of multinational company trained experts with an average of 10 – 20 years of international industrial experience; (2) it has a very promising product pipeline, and (3) its team has an extensive network and ability for leveraging international resources and transferring technologies. 


Zerun’s core value is ingrained in its R&D team. Zerun has been building skilled team and innovation technology since its inception. The top management team has on average of 20 years of working experience in the world’s top multinational companies such as Merck, GSK and Amgen. The company’s core technical team has over 10 years of industrial experience. The R&D team is well educated with 62% of them holding Masters degree or above, 30% with Bachelor degree, and 10% with oversea training or working experiences. 


The company develops innovative vaccines based its four platform technologies as follows: 

1. Recombinant protein/antigen expression systems in yeast, insect cells and E. coli; 
2. Recombinant “Virus-Like Particle" (VLP) antigen production and characterization technology; 
3. Novel adjuvant development, production and assessment platform technology;
4. Inactivated virus based vaccine development technologies.

Using above aforementioned vaccine development systems and technologies, the company has developed a series of products including the human papillomavirus vaccine (HPV), which is under phase III clinical trial and commercial manufacturing preparation. Zerun also has multiple of other recombinant vaccine products that are currently in the late pre-clinical development stage, which possess vast market potential. 


Zerun also focuses on and maintain intellectual property rights to protect its innovative product development programs with several dozens of patent applications and two dozen approved in China and oversea.